Publications by authors named "Steven D Knight"

Claim this Profile
A
Asymmetric synthesis of potent and orally bioavailable thiophene-based EZH2 inhibitors.
Xinrong Tian, Ken Newlander, Louis LaFrance, James Mack, James Brackley, Steven D Knight

Bioorg Med Chem Lett· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Signaling function of PRC2 is essential for TCR-driven T cell responses.
Marc-Werner Dobenecker, Joon Seok Park, Jonas Marcello, Michael T McCabe, Richard Gregory, Steven D Knight

J Exp Med· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent Class of PI3Kα Inhibitors with Unique Binding Mode via Encoded Library Technology (ELT).
Hongfang Yang, Patricia F Medeiros, Kaushik Raha, Patricia Elkins, Kenneth E Lind, Steven D Knight

ACS Med Chem Lett· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.
Heidi M Ott, Alan P Graves, Melissa B Pappalardi, Michael Huddleston, Wendy S Halsey, Steven D Knight

Mol Cancer Ther· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer.
Sharad K Verma, Steven D Knight

Future Med Chem· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.
Sharad K Verma, Xinrong Tian, Louis V LaFrance, Céline Duquenne, Dominic P Suarez, Steven D Knight

ACS Med Chem Lett· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295.
Xiangping Qian, Andrew McDonald, Han-Jie Zhou, Nicholas D Adams, Cynthia A Parrish, Steven D Knight

ACS Med Chem Lett· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin.
Steven D Knight, Nicholas D Adams, Joelle L Burgess, Amita M Chaudhari, Michael G Darcy

ACS Med Chem Lett· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of an allosteric inhibitor of centromere-associated protein-E.
Kenneth W Wood, Latesh Lad, Lusong Luo, Xiangping Qian, Steven D Knight

Proc Natl Acad Sci U S A· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent progress in the identification and clinical evaluation of inhibitors of the mitotic kinesin KSP.
Steven D Knight, Cynthia A Parrish

Curr Top Med Chem· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides.
Jian Jin, Ming An, Anthony Sapienza, Nambi Aiyar, Diane Naselsky, Steven D Knight

Bioorg Med Chem Lett· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel ATP-competitive kinesin spindle protein inhibitors.
Cynthia A Parrish, Nicholas D Adams, Kurt R Auger, Joelle L Burgess, Jeffrey D Carson, Steven D Knight

J Med Chem· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.
Stephen A Douglas, David J Behm, Nambi V Aiyar, Diane Naselsky, Jyoti Disa, Steven D Knight

Br J Pharmacol· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists.
Jian Jin, Dashyant Dhanak, Steven D Knight, Katherine Widdowson, Nambi Aiyar

Bioorg Med Chem Lett· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist.
David J Behm, Christopher L Herold, Eliot H Ohlstein, Steven D Knight, Dashyant Dhanak

Br J Pharmacol· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis